Exchange: NASDAQ·Updated 12:16 PM EDT

AMGN News

News
all
press releases
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks
More News
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus
Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.
Zacks
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireSAN DIEGO, Sept. 28, 2026 SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary- For most of the last four decades, RAS was the target oncology...
PR Newswire
2 Healthcare Stocks That Just Delivered Great News for Investors
Key PointsVertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates...
Nasdaq News: Markets
Amgen (AMGN) Rises Higher Than Market: Key Facts
In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.
Zacks
Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields
Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.
Zacks
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Zacks
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Zacks
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’
In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.
Stocktwits
Amgen Hits Primary Endpoint In Sjogren's Trial, But Approval Filing Awaits Another Trial Data
Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sj?gren's disease.read more...
Benzinga

Advertisement|Remove ads.